

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/IL05/001280

International filing date: 30 November 2005 (30.11.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/657,718  
Filing date: 03 March 2005 (03.03.2005)

Date of receipt at the International Bureau: 19 December 2005 (19.12.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

07 DEC 2005

PA 1396682

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

November 25, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/657,718


FILING DATE: March 03, 2005

THE COUNTRY CODE AND NUMBER OF YOUR PRIORITY APPLICATION, TO BE USED FOR FILING ABROAD UNDER THE PARIS CONVENTION, IS US60/657,718

By Authority of the  
Under Secretary of Commerce for Intellectual Property  
and Director of the United States Patent and Trademark Office



M. TARVER  
Certifying Officer




**U.S. PATENT AND TRADEMARK OFFICE**  
**PROVISIONAL APPLICATION FOR PATENT COVER SHEET**

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT  
 under 37 C.F.R. §1.53(b)(2)

Atty. Docket: FISHMAN20

112975 U.S.PTO  
 60/657718

INVENTOR(S)/APPLICANT(S)			
LAST NAME	FIRST NAME	MI	RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY)
FISHMAN	Pnina		Herzliya, Israel
BAR YEHUDA	Sara		Rishon Le Zion, Israel
MADI	Lea		Rishon Le Zion, Israel
<input type="checkbox"/> Additional inventors are being named on separately numbered sheets attached hereto.			
TITLE OF THE INVENTION (500 characters max)			
A BIOLOGICAL MARKER FOR INFLAMMATION			
CORRESPONDENCE ADDRESS			
Direct all correspondence to the address associated with Customer Number 001444, which is presently:			
BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W., Suite 300 Washington, D.C. 20001-5303			
ENCLOSED APPLICATION PARTS (check all that apply)			
<input checked="" type="checkbox"/> Specification	Number of Pages <u>22</u>	<input type="checkbox"/> Other _____	
<input checked="" type="checkbox"/> Drawings	Number of Pages <u>5</u>		
FEES AND METHOD OF PAYMENT OF FILING FEES (check all that apply)			
<input checked="" type="checkbox"/> Basic Filing fee <span style="float: right;">\$ 200.00</span>			
<input type="checkbox"/> Additional Fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250.00 for each additional 50 sheets of paper or fraction thereof.			
Total Sheets	Extra Sheets	# of each additional 50 (round up to a whole number)	RATE
27 - 100 =	/ 50 =		× 250.00
SUB-TOTAL <span style="float: right;">\$ 200.00</span>			
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. <span style="float: right;">&lt;\$ 100.00&gt;</span>			
<input checked="" type="checkbox"/> Credit Card Payment Form PTO-2038 is enclosed to cover the total filing fees. <span style="float: right;">TOTAL FILING FEES <b>\$ 100.00</b></span>			
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any underpayment of filing fees and credit any overpayments to Deposit Account Number 02-4035.			
The invention was made by an agency of the United Stated Government or under a contract with an agency of the United States Government.			
<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____			

Respectfully submitted,  
 BROWDY AND NEIMARK, P.L.L.C.  
 By:   
 Sheridan Neimark  
 Registration No.: 20,520

Date: 03/03/05

SN:ccw

## A BIOLOGICAL MARKER FOR INFLAMMATION

5

### FIELD OF THE INVENTION

This invention relates to the fields of diagnosis and determining effectiveness of treatment and in particular to biological markers associated with inflammatory states.

### 10 PRIOR ART

The following is a list of prior art which is considered to be pertinent for describing the state of the art in the field of the invention. Acknowledgement of these references herein will at times be made by indicating their number within brackets from the list below.

15 1. Fishman P, Madi L, Bar-Yehuda S, Barer F, Del Valle L, Khalili K. Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. *Oncogene*, 21:4060-4064 (2002).

20 2. Fishman P, Bar-Yehuda S, Rath-Wolfson L, Ardon E, Barrer F, Ochaion A, Madi L. Targeting the A3 adenosine receptor for cancer therapy: inhibition of Prostate carcinoma cell growth by A<sub>3</sub>AR agonist. *Anticancer Res.*, 23:2077-2083 (2003).

25 3. Madi L, Bar-Yehuda S, Barer F, Ardon E, Ochaion A, Fishman P. A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition. *J. Bio. Chem.*, 278:42121-42130 (2003).

4. Ohana G, Bar-Yehuda S, Arich A, Madi L, Dreznick Z, Silberman D, Slosman G, Volfsson-Rath L, Fishman P. Inhibition of primary colon

01579515\3-01

carcinoma growth and liver metastasis by the A3 adenosine receptor agonist IB-MECA. *British J. Cancer.*, 89:1552-1558 (2003).

5. Fishman P, Bar-Yehuda S, Ohana G, Ochaion A, Engelberg A, Barer F, Madi L. An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 $\beta$  and NF- $\kappa$ B. *Oncogene*, 23:2465-2471 (2004).
6. US Patent Application No. 2004016709 A1.
7. Szabo, C., et al. Suppression of macrophage inflammatory protein (MIP)-1 $\alpha$  production and collagen-induced arthritis by adenosine receptor agonists. *British J. Pharmacology*, 125:379-387 (1998).
8. Mabley, J., et al. The adenosine A<sub>3</sub> receptor agonist, N<sup>6</sup>-(3-iodobenzyl)-adenosine -5'-N-methyluronamide, is protective in two murine models of colitis. *Europ. J. Pharmacology*, 466:323-329 (2003).
9. Baharav, E., et al. The effect of adenosine and the A<sub>3</sub> adenosine receptor agonist IB-MECA on joint inflammation and autoimmune diseases models. *Inter. J. Mol. Med.* 10(supplement 1) page S104, abstract 499 (2002).
10. Montesinos, M. Carmen, et al. Adenosine A<sub>2A</sub> or A<sub>3</sub> receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. *Arthritis & Rheumatism*, 48:240-247 (2003).
11. Madi L, Ochaion A, Rath-Wolfsen L, Bar-Yehuda S, Erlanger A, Ohana G, Harish A, Merimski O, Barer F, Fishman P. The A3 Adenosine Receptor is Highly Expressed in Tumor vs. Normal Cells: Potential Target for Tumor Growth Inhibition. *Clinical Cancer Research*, 10: 4472-4479, 2004.
12. Gessi, S. et al. Elevated expression of A<sub>3</sub> adenosine receptors in human colorectal cancer is reflected in peripheral blood cells *Clinical Cancer Research* 10:5895-5901, 2004
13. US Patent Application No. 20040137477 A1.

01579515\3-01

## BACKGROUND OF THE INVENTION

The A<sub>3</sub> adenosine receptor, a G<sub>i</sub> protein-associated cell surface receptor, has been found to be utilized as a target to combat cancer and inflammation. The receptor is highly expressed in various tumor cell types 5 while low expression was shown in adjacent normal tissues. Activation of the receptor by a specific synthetic agonist induces modulation of downstream signal transduction pathways which include the Wnt and the NF- $\kappa$ B, resulting in tumor growth inhibition (1-5).

*In vivo* studies have shown that A<sub>3</sub>AR agonists inhibit the 10 development of colon, prostate and pancreatic carcinomas as well as melanoma and hepatoma.

A<sub>3</sub>AR agonists were also been shown to act as anti-inflammatory agents by ameliorating the inflammatory process in different experimental autoimmune models such as rheumatoid arthritis and Crohn's disease (6-9). It 15 was proposed also that the A<sub>2A</sub> and A<sub>3</sub> receptors mediate the anti-inflammatory effects of methotrexate (10).

A<sub>3</sub> adenosine receptor (A<sub>3</sub>AR) expression levels are elevated in cancer cells as compared to normal cells (11,12). Thus, the A<sub>3</sub>AR expression level has been described as a means for the diagnosis of cancer (13). In 20 addition, A<sub>3</sub>AR expression levels have also been described to be elevated in peripheral blood cells of patients with colorectal cancer (12).

## SUMMARY OF THE INVENTION

It is an object of the invention to provide a method for determining an inflammatory state in a subject.

25 Another object of the invention to provide a method for determining the severity of an inflammatory state in a subject.

It is a further object of the invention to provide a method for determining the effectiveness of an anti-inflammatory therapeutic treatment of a subject.

It is yet a further object of the invention to provide a method for selecting subjects to receive anti-inflammatory therapeutic treatment.

The present invention is based on the surprising finding that there is an increase in the level of A<sub>3</sub> adenosine receptor expression in the WBC of a subject who has an inflammatory condition as compared to the WBC of a healthy subject. Furthermore, it was found that in subjects who respond to anti-inflammatory drug treatment, there is a reduction in the level of A<sub>3</sub> adenosine receptor expression in their WBC. This finding paves the way for the use of the A<sub>3</sub> adenosine receptor expression level as a means for the diagnosis of an inflammatory state, as well as other applications described below.

In a first aspect of the invention, there is provided a method of determining an inflammatory state in a subject, comprising:

- (a) obtaining from the subject a sample comprising white blood cells (WBC); and
- (b) determining the level of expression of A<sub>3</sub> adenosine receptor (A<sub>3</sub>AR) in the WBC of the sample, wherein a high level of expression is indicative of an inflammatory state in the subject.

In a second aspect of the invention, there is provided a method for determining the severity of an inflammatory state in a subject comprising:

- (a) obtaining from the subject a sample comprising WBC;
- (b) determining the level of expression of A<sub>3</sub>AR in the WBC of the sample;
- (c) comparing the level of expression of A<sub>3</sub>AR in the cells with the level of prior determined or obtained standards, to determine the severity of the inflammatory state of the subject.

In a third aspect of the invention, there is provided a method for determining the effectiveness of an anti-inflammatory therapeutic treatment of a subject comprising:

(a) obtaining from the subject samples comprising white blood cells (WBC) from at least two discrete time points, at least one of which is during anti-inflammatory treatment; and

(b) determining the level of expression of A<sub>3</sub>AR in the WBC of the samples, wherein a difference is indicative of the effectiveness of the anti-inflammatory therapeutic treatment.

The sample comprising WBC may be whole blood or may be a blood fraction that contains WBC. At times, it may be desired to use a fraction that includes a specific population of WBC such as mononuclear cells (MNC),  
10 sub-populations of MNC – monocytes or lymphocytes, or a sub-population of lymphocytes, e.g. T-cells, B-cell or their sub-populations. A WBC-comprising sample may also at times be obtained from the lymphatic system, e.g. from lymph nodes.

The therapeutic treatment may be any type of treatment given to a patient with an inflammatory condition, including drug treatment. Drugs for treatment of inflammatory conditions are well known and include disease modifying drugs such as Methotrexate or prednisone; non steroidal anti-inflammatory drugs (NSAIDs) such as Diclofenac, Diflunisal, Etodolac, Fenoprofen, Flurbiprofen, Ibuprofen, Indomethacin, Ketoprofen,  
20 Meclofenamate, Nabumetone, Naproxen, Oxaprozin, Phenylbutazone, Piroxicam, Sulindac, Tenoxicam, Tiaprofenic Acid, or Tolmetin; anti-TNF drugs such as etanercept, adalimumab, or infliximab; and A<sub>3</sub>AR agonists such as N6-(3-iodobenzyl) adenosine-5'-N-methyl- uronamide (IB-MECA) or 2-chloro-N<sup>6</sup>-(3-iodobenzyl)-adenosine-5'-N-methyl-uronamide (Cl-IB-MECA); as well as others. A<sub>3</sub>AR agonists such as IB-MECA and Cl-IB-MECA are preferred drugs according to the invention.

The term "*level of expression*" as used herein includes both the level of A<sub>3</sub>AR mRNA as well as the level of A<sub>3</sub>AR protein or A<sub>3</sub>AR protein fragments in the sampled cells.

30 The A<sub>3</sub>AR level of expression in WBC in accordance with some embodiments of the invention may be used for determination of the state or

severity of inflammation, e.g. for determining the presence or absence of an inflammatory state. In accordance with other embodiments of the invention, the A3AR level of expression may be used for quantitative determination of the degree of severity of the inflammatory state. The term "*determining*" or 5 "*determination*" will be employed below to refer to either or both quantitative or qualitative determination.

An "*inflammatory state*" includes any state of active or sub-clinical inflammation. The inflammation may be due to an inflammatory disease, or it may be a side effect of some other type of disease or disorder. Examples of 10 inflammatory diseases include but are not limited to inflammatory bowel diseases, inflammatory corpuscle, inflammatory fibrous hyperplasia, inflammatory gallbladder disease, inflammatory papillary hyperplasia and autoimmune diseases.

The autoimmune diseases may include any of the following:

15 Myasthenia Gravis (MG), Congenital myasthenia gravis, Multiple sclerosis (MS), Stiff-man syndrome, Tropical spastic paraparesis, Rasmussen's encephalitis, Acute motor axonal neuropathy, Acute sensory-motor axonal neuropathy, Dorsal root ganglion neuritis, Acute pan-autonomic neuropathy, Brachial neuritis, Acute necrotizing hemorrhagic lekoencephalitis, Sporadic 20 necrotizing myelopathy, Paraneoplastic cerebellar degeneration, Guillain-Barre syndrome, Limbic encephalitis, Opsoclonus-myoclonus ataxia, Sensory neuronitis, Autonomic neuropathy, Demyelinating neuropathy, AIDS-dementia complex, Tourette's syndrome, Miller-Fisher syndrome, Alzheimer's disease, Graves' Disease, Hashimoto's thyroiditis, Postpartum 25 thyroiditis, Focal thyroiditis, Juvenile thyroiditis, Idiopathic hypothyroidism, Type I (insulin dependent) diabetes mellitus, Addison's disease, Hypophysitis, Autoimmune diabetes insipidus, Hypoparathyroidism, Pemphigus Vulgaris, Pemphigus Foliaceus, Bullous pemphigoid/ Pemphigoid gestationis, Cicatrical pemphigoid, Dermatitis herpetiformis, 30 Epidermal bullosa acquisita, Erythema multiforme, Herpes gestatonis, Vitiligo, Chronic urticaria, Discoid lupus, Alopecia universalis/Areata,

Psoriasis, Autoimmune hepatitis, Primary biliary cirrhosis, Chronic active hepatitis, Chronic active hepatitis/ Primary biliary cirrhosis overlap syndrome, Primary sclerosing cholangitis, Autoimmune hemolytic anemia, Idiopathic thrombocytopenic purpura, Evans syndrome, Heparin-induced

5 thrombocytopenia, Primary autoimmune neutropenia, Autoimmune (primary) neutropenia of infancy, Autoimmune neutropenia following bone marrow transplant, Acquired autoimmune hemophilia, Autoimmune gastritis and pernicious anemia, Coeliac disease, Crohn's disease, Ulcerative colitis, Sialadenitis, Autoimmune premature ovarian failure, Azoospermia,

10 Hypogonadism, Male infertility associated with sperm autoantibodies, Autoimmune orchitis, Premature ovarian failure, Autoimmune oophoritis, Uveitis, Retinitis, Sympathetic ophthalmia, Birdshot retinochoroidopathy, Vogt-Koyanagi-Harada granulomatous uveitis, Retinal degeneration, Lens-induced uveitis, Optic neuritis, Autoimmune sensorineural hearing loss,

15 Meniere's disease, Autoimmune myocarditis, Congenital heart block (neonatal lupus), Chagas' disease, Adriamycin cardiotoxicity, Dressler's myocarditis syndrome, Bronchial asthma, Interstitial fibrosing lung disease, Rapidly progressive glomerulonephritis, Autoimmune tubulointerstitial nephritis, Systemic lupus erythematosus (SLE), Antiphospholipid syndrome,

20 Rheumatoid arthritis, Juvenile Rheumatoid arthritis, Felty's syndrome, Large granular lymphocytosis (LGL), Sjogren's syndrome, Systemic sclerosis (scleroderma), Crest syndrome, Mixed connective tissue disease, Polymyositis/dermatomyositis, Goodpasture's Disease, Wegener's granulomatosis, Churg-Strauss syndrome, Henoch-Schonlein purpura,

25 Microscopic polyangiitis, Periarteritis nodosa, Bechet's syndrome, Atherosclerosis, Temporal (giant) cell arteritis, Takayasu arteritis, Kawasaki disease, Ankylosing spondilitis, Reiter's disease, Sneddon's disease, Autoimmune polyendocrinopathy, candidiasis-ectodermal dystrophy, Essential cryoglobulinemic vasculitis, Cutaneous leukocytoclastic angiitis, Lyme

30 disease, Rheumatic fever and heart disease, Eosinophilic fasciitis, Paroxysmal cold hemoglobinuria, Polymyalgia rheumatica, Fibromyalgia, POEMS

syndrome (polyneuropathy, organomegaly, endocrinopathy, M-spot and skin changes), Relapsing polychondritis, Autoimmune lymphoproliferative syndrome, TINU syndrome (acute tubulointerstitial nephritis and uveitis), Common variable immunodeficiency, TAP (transporter associated with antigen presentation) deficiency, Omenn syndrome, HyperIgM syndrome, BTK agammaglobulinemia, Human immunodeficiency virus and Post bone-marrow-transplant.

The sample comprising WBC used in the methods of the invention may include any of the known types of cells which make up this group. In particular, the sample should preferably include mononuclear cells (monocytes and/or lymphocytes). At times, the sample may include in addition, or in the alternative, granulocytes (neutrophils, eosinophils or basophils).

In a first embodiment, a high level of expression of A<sub>3</sub>AR is employed as an indicator of an inflammatory state in the subject. The term "*high level*" is to be understood as meaning a significantly higher level of expression than in normal cells. For example, the level of the A<sub>3</sub>AR expression in the WBC may be compared to a control level, the control level being the level of A<sub>3</sub>AR expression in normal WBC of a healthy subject. At times it may be useful to determine the expression level by testing an assayed sample from an individual in parallel to one or more reference standards, e.g. one reference standard indicative of a normal state and another indicative of an inflammatory state.

In a second embodiment, the determined expression level is compared to standards. The standards may be based on previously determined levels from healthy individuals and from individuals with an inflammatory state or with different inflammatory states. The standards may be provided, for example, in the form of discrete numeric values or, in case the assay method is colorimetric, in the form of a chart with different colors or shadings for healthy and inflammatory states; or they may be provided in the form of a comparative curve prepared on the basis of such standards.

Such standards may be prepared by determining the level of A<sub>3</sub>AR expression (which may be the level of A<sub>3</sub>AR protein, protein fragment, or mRNA level etc., as discussed above) present in WBC cells obtained from a plurality of patients positively diagnosed (by other means, for example by a physician, by histological techniques etc.) as having inflammation at varying levels of severity. The severity of the disease for the preparation of the standards may also be determined by various conventional methods such as by pathological techniques. In another embodiment, the assay is carried out in parallel to a number of standards of healthy subjects and subjects of different inflammatory states and the level determined in the assayed sample is then compared to such standards.

For example, a protein content level of between X<sub>1</sub> to X<sub>2</sub> per 1,000,000 cells may be defined as being indicative of grade 1 inflammation, a higher protein content of Y<sub>1</sub> to Y<sub>2</sub> per 1,000,000 cells may be defined as being indicative of grade 2 inflammation, etc. After such standards are prepared, it is possible to compare the level of A<sub>3</sub>AR expression obtained from a specific individual to the corresponding value of the standards, and thus obtain an assessment of the severity of the disease.

The effectiveness of an anti-inflammatory therapeutic treatment of a subject may be assessed by taking samples of WBC at various time points before, during and after the treatment. For example, a first sample may be taken at a time point prior to initiation of the treatment and a second sample may be taken at a time point during the treatment. A decrease in the level of the A<sub>3</sub>AR expression in the second sample as compared to the first sample would be indicative that the treatment is effective. The degree of decrease could be indicative of the degree of effectiveness of the treatment, i.e. the correlation would be quantitative.

In another example, a first sample may be taken at a time point during the treatment and a second sample may be taken at a time point during the treatment subsequent to the time point of the first sample. A decrease in the

level of the A<sub>3</sub>AR expression in the second sample as compared to the first sample would be indicative that the treatment is effective.

In a third example, a first sample may be taken at a time point during the treatment and a second sample may be taken at a time point after the 5 treatment has been discontinued. In this case, an increase in the level of the A<sub>3</sub>AR expression in the second sample as compared to the first sample would be indicative that the treatment is effective.

Of course, various other combinations may be carried out, as well as the taking of samples at more than two time points.

10 The invention also provided a method for selecting a subject to receive anti-inflammatory therapeutic treatment comprising:

- (a) obtaining from the subject a sample comprising WBC;
- (b) determining the level of expression of A<sub>3</sub>AR in the WBC of the sample;
- 15 (c) comparing the level of expression of A<sub>3</sub>AR in the cells with the level of prior determined or obtained standards;

wherein a level of expression of A<sub>3</sub>AR in the cells is above said standards, the subject is selected from anti-inflammatory therapeutic treatment.

20 Selection of subjects suitable for anti-inflammatory treatment may be executed by determining the level of expression of A<sub>3</sub>R in a sample of WBC withdrawn from said subject before treatment. The subject is selected if the determined level of A<sub>3</sub>AR is above a predefined threshold.

According to one embodiment, the threshold is determined as the level 25 of A<sub>3</sub>AR expression in normal WBC of a healthy subject, or being a standard reference level for the A<sub>3</sub>AR expression which is indicative of a normal state.

The selection method may also apply for selecting candidates for participating in clinical studies to test anti-inflammatory treatments. As appreciated by those versed in the art, a clinical study (also known by the 30 terms 'clinical trial' or 'clinical protocol'), is a scientific study in human volunteers to determine how a new medicine or treatment works in human

subjects. Interventional trials determine whether experimental treatments or new ways of using known therapies are safe and effective under controlled environments. It is through clinical studies that physicians find new and better ways to prevent, detect, diagnose, control, and treat illnesses. The clinical  
5 studies for which patients are selected, in accordance with the invention, based on the A<sub>3</sub>AR level may be Phase I, Phase II, Phase III, Phase IV or any other type of clinical study.

For clinical studies the threshold according to the invention may also be of an abnormal (higher than normal) level of expression of A<sub>3</sub>AR. An  
10 abnormal level may be defined based on considerations known to those experienced in clinical studies to be a suitable threshold for selecting such candidates.

#### BRIEF DESCRIPTION OF THE FIGURES

15 In order to understand the invention and to see how it may be carried out in practice, a preferred embodiment will now be described, by way of non-limiting example only, with reference to the accompanying drawings, in which:

20 **Figs. 1A – 1D** are Western blots and the corresponding bar graphs of average blot intensity and standard deviation showing that A<sub>3</sub>AR is up-regulated in inflammatory and hematopoietic tissues upon occurrence of inflammation.

25 **Fig. 2** is a Western blot and the corresponding bar graph of average blot intensity and standard deviation showing that the level of expression of A<sub>3</sub>AR correlates with Disease Clinical Score in AIA model. "0" indicates Naïve animals (animals without inflammation) and "6", "9" and "12" relate to inflamed animals and the numbers indicate the inflammatory score in these animals.

30 **Fig. 3** is a graph showing the change in severity of arthritis as a function of time in control animals and in AIA animals treated with either

methotrexate (MTX), CF101 (clinical grade IB-MECA), a combination of MTX and CF101 or vehicle only (control).

**Figs. 4A – 4B** are Western blots and the corresponding bar graphs showing A<sub>3</sub>AR protein expression level in lymph node (Fig. 4A) and spleen 5 (Fig. 4B) cells in naïve animals, in AIA animal and in AIA animals after CF101 (clinical grade IB-MECA) treatment.

**Figs. 5A – 5C** are Western blots and the corresponding bar graphs showing A<sub>3</sub>AR protein expression level in paw (Fig. 5A), synovial tissue (Fig. 5B) and peripheral blood mononuclear cell (Fig. 5C) in AIA either 10 vehicle treated or treated with CF101.

**Fig. 6** is a Western blot and the corresponding bar graph showing A<sub>3</sub>AR protein expression level in lymph nodes in naïve animals, AIA animals and in AIA animals treated with MTX.

**Fig. 7** is a Western blot and the corresponding bar graph showing 15 A<sub>3</sub>AR protein expression level in 7 healthy subjects and in 7 RA patients.

**Fig. 8** is a bar graph showing A<sub>3</sub>AR level in peripheral blood mononuclear cells of RA patients before and after 3 months of treatment with CF101, from 3 non-responders which are patients that did not respond to the treatment (had no ACR 20 response by ACR criteria – criteria for clinical 20 response of the American College of Rhuematology) and 5 responders who had an ACR 20 or higher response.

**Fig. 9** is a bar graph showing correlation between patients' A<sub>3</sub>AR level at baseline and clinical efficacy parameters of the patients of Fig. 8.

**Fig. 10** is a bar graph showing the correlation between patients' A<sub>3</sub>AR 25 level at baseline and clinical response as measured by ACR criteria, of the patients of Fig. 8.

## DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT

### Materials and Methods

#### *Induction of adjuvant induced arthritis (AIA) model in rats*

Female Lewis rats, aged 8-12 weeks were obtained from Harlan Laboratories (Jerusalem, Israel). Rats were maintained on a standardized pelleted diet and supplied with tap water. Experiments were performed in accordance with the guidelines established by the Institutional Animal Care and Use Committee at Can-Fite BioPharma, Petah Tikva, Israel. The rats were injected subcutaneously (SC) at the tail base with 100  $\mu$ l of suspension composed of incomplete Freund's adjuvant (IFA) with 10 mg/ml heat killed *Mycobacterium tuberculosis*, (Mt) H37Ra, (Difco, Detroit, USA). Each group contained 10 animals.

Treatment with IB-MECA (10  $\mu$ g/kg) was initiated on day 14 after vaccination and was orally administered by gavage, twice daily. Another group was treated with Methotrexate (MTX) (1.5 mg/kg) intraperitoneally every 3 days, starting on day 14th after vaccination. The control group in each experiment received vehicle only (DMSO in a dilution corresponding to that of the drugs).

Clinical Disease Activity Score was assessed as follows: the animals were inspected every second day for clinical arthritis. The scoring system ranged from 0-4 of each limb: 0- no arthritis; 1- redness or swelling of one toe/finger joint; 2- redness and swelling of more than one toe/finger joints, 3- the ankle and tarsal-metatarsal joints involvement. 4- entire paw redness or swelling. The clinical score was calculated by adding the four individual legs' score. The inflammatory intensity was also determined in accordance with the increase in the rat hind paw's diameter, measured by caliper (Mitutoyo, Tokyo, Japan).

***Separation of inflammatory and hematopoietic tissues and preparation of protein extracts***

***a. Inflammatory Tissues***

The hind paws were dissected above the ankle joint. The bony tissue  
5 was broken into pieces, snap frozen in liquid nitrogen and stored at -80°C until use. To prepare a protein extract, RIPA buffer (containing 150mM NaCl, 50mM Tris, 1% NP40, 0.5% Deoxycholate and 0.1% SDS) was added to the paw tissue (4 ml/gr of tissue). The mixture was homogenized on ice with a polytron and centrifuged.

10 Synovial tissue was removed and synovial cells were separated by incubating the tissue in RPMI containing 1 mg/ml Collagenase IV and 0.1mg/ml DNase with a vigorous shaking (200 rpm) at 37°C for 30 min. The supernatant containing the synovial cells was collected and the undigested tissue was re-extracted. The supernatants from both extractions were  
15 combined and cells were washed with PBS. Protein extracts were prepared.

***b. Hemopoietic Tissues***

Lymph nodes were removed and cells were separated by first mincing the tissue and disaggregating it through a needle of 22 G. Spleens were removed and subjected to Lymphoprep (Nycomed AS, Oslo, Norway) for  
20 mononuclear cell separation. Protein extracts were prepared.

***Separation of peripheral blood mononuclear cells from RA patients and healthy subjects***

Blood was withdrawn from healthy subjects or RA patients.  
25 Mononuclear cells (lymphocytes and monocytes) were separated using Ficoll-Hypaque gradient. Protein was extracted from the mononuclear cells.

***Clinical Study***

01579515\3-01

Blood was withdrawn from RA patients who were enrolled in a clinical study in which the effect of CF101, a clinical grade IB-MECA, on arthritic patients was evaluated. The patients randomly received 0.1, 1.0 or 4.0 mg of CF101 twice daily. Blood was withdrawn at 2 time points: (a) after 5 a washout period of 4-6 weeks from a previous treatment and before CF101 treatment was initiated – this was considered as baseline level; (b) after 3 months of treatment with CF101. Peripheral blood mononuclear cells were separated and protein was extracted as described above. In addition, C reactive protein (CRP) values were analyzed, the number of tender and 10 swollen joints, the physicians global assessment, the patient own assessment, the pain score and the disability score were recorded and the ACR score was calculated for each patient (ACR is a parameter which was determined by the American College of Rheumatology to predict the response of patient to a given drug; ACR 20, ACR 50 and ACR 70 respectively represent a 20%, 15 50% and 70% improvement in these parameters).

*Analysis of A<sub>3</sub>AR protein expression level by Western Blot (WB) analysis*

Western blot analysis (WB) of synovial, paw, spleen and lymph nodes were carried out according to the following protocol. Samples were rinsed 20 with ice-cold PBS and transferred to ice-cold lysis buffer (TNN buffer, 50mM Tris buffer pH=7.5, 150mM NaCl, NP 40). Cell debris was removed by centrifugation for 10 min, at 7500xg. Protein concentrations were determined using the Bio-Rad protein assay dye reagent. Equal amounts of the sample (50µg) were separated by SDS-PAGE, using 12% polyacrylamide 25 gels. The resolved proteins were then electro-blotted onto nitrocellulose membranes (Schleicher & Schuell, Keene, NH, USA). Membranes were blocked with 1% BSA and incubated with the primary antibody against A<sub>3</sub>AR (dilution 1:1000) for 24h at 4°C. Blots were then washed and incubated with a secondary antibody for 1h at room temperature. Bands were

recorded using BCIP/NBT color development kit (Promega, Madison, WI, USA).

## RESULTS

### ***A3AR is up-regulated in inflammatory and hematopoietic tissues***

5 The level of expression of A3AR in AIA model was determined by WB analysis. To this end, protein extracts from inflamed tissue (paw) or from peripheral hematopoietic tissue (peripheral blood mononuclear cells, lymph nodes and spleen) were obtained and analyzed as described in the Materials and Methods. Figs 1A-1D present WB analysis results, also presented in  
10 corresponding bar graphs, which give average results and the standard deviation. As shown, A3AR is up-regulated in inflamed tissue (Fig. 1A) as well as in peripheral hematopoietic tissues (Figs. 1B-1D).

The level of expression of A3AR in AIA model correlated also with Disease Clinical Score (Fig. 2) providing further evidence for the correlation  
15 between inflammation and A3AR expression.

### ***CF101 inhibits the development of AIA***

About 21 days after immunization, most of the vehicle treated animals progressively developed arthritis. CF101 treatment (10 µg/kg, given orally twice daily, starting on day 14th after immunization) and methotrexate  
20 (MTX) treatment resulted in a significant decrease in disease severity, very similar for both drugs, as was evaluated by the arthritis clinical score. Disease peaked on days 21-28 and maximal effect of CF101 or MTX was seen on these days (Fig. 3).

### ***A3AR is highly expressed in inflammatory tissues and in peripheral hematopoietic tissues of AIA rats***

Low A3AR expression level was detected in the healthy paw & synovial tissues. In the inflammatory tissues derived from AIA rats, a marked increase in the A3AR protein expression level was noted (Figs. 4A-4B). Upon  
01579515\3-01

IB-MECA treatment A<sub>3</sub>AR level was down-regulated (Figs. 4A-4B). A similar pattern was noted in the peripheral hematopoietic tissues, i.e., low A<sub>3</sub>AR expression level was noted in the spleen and lymph node (LN) derived from naïve animals, high in the tissues from AIA and low expression in the 5 tissues of IB-MECA treated rats (Figs. 5A - 5C). In LN derived from AIA rats treated with MTX, a similar A<sub>3</sub>AR expression profile was observed (Fig. 6).

***High A<sub>3</sub>AR expression is found in MNC derived from RA vs. low in healthy subjects***

10 Low A<sub>3</sub>AR expression level was found in MNC from healthy subjects whereas high expression was detected in MNC derived from RA patients (Fig. 7).

***Correlation between A<sub>3</sub>AR expression and clinical efficacy parameters***

15 The direct correlation between the clinical response and receptor down-regulation led to the conclusion that A<sub>3</sub>AR expression may be suggested as a surrogate marker to predict response to a given anti-inflammatory treatment.

20 Blood was withdrawn from 8 patients who participated in a clinical study for testing the effect of CF101 on the manifestation of disease in such patients. The blood was withdrawn following a washout period from previous treatment and then after 3 months of treatment, peripheral blood mononuclear cells (PBMNC) were separated and the level of A<sub>3</sub>AR was determined in these cells. Out of these 8 patients, 3 were non-responders, namely these patients have not even achieved an ACR 20 response, while the other 5 were 25 responders as they had at least an ACR 20 response (as can be seen in Fig. 10, 3 of the responders had an ACR 70 response, 1 achieved an ACR 50 response and another 1 an ACR 20 only response; note that the bar graph for the ACR 50 responders in Fig. 10, includes also the 3 ACR 70 responders, while the

bar graph of the ACR 20 responders includes also the ACR 50 and ACR 70 responders).

Fig. 8 shows the A<sub>3</sub>AR level in the responders and non-responders at the two time points mentioned above. It can clearly be seen that all responders 5 had an initial high level of A<sub>3</sub>AR, which was lowered after 3 months treatment, while there was essentially no change in the A<sub>3</sub>AR level in the non-responders.

The correlation between the level of expression of the A<sub>3</sub>AR and change in different clinical parameters can be seen in Fig. 9. It can be clearly 10 seen that in all the evaluated clinical parameters (number of tender joints, number of swollen joints, physician assessment, patient assessment, pain score, CRP score and disability score), the patients that had initially a higher A<sub>3</sub>AR level in their PBMC, had a better clinical response in all the tested parameters, as compared to those that had an initial low level of A<sub>3</sub>AR.

15 The ACR response of these patients is shown in Fig. 10. As can be seen, none of the 3 patients that had an initial low A<sub>3</sub>AR level, had an ACR 20 response (and hence also no ACR 50 or ACR 70 response). In contrast, of those 5 patients that had a high A<sub>3</sub>AR level, 3 achieved an ACR 70 response, 1 an ACR 50 response and 1 an ACR 20 response.

20 These data clearly demonstrate the ability to use the A<sub>3</sub>AR level in order to predict a response of patient to an anti-inflammatory drug therapy, particularly such therapy which makes use of an A<sub>3</sub>AR agonists as a disease modifying drug.

25

01579515\3-01

**CLAIMS:**

1. A method of determining an inflammatory state in a subject, comprising:
  - (a) obtaining from the subject a sample comprising white blood cells (WBC); and
  - (b) determining the level of expression of A<sub>3</sub> adenosine receptor (A<sub>3</sub>AR) in the WBC of said sample, wherein a high level of expression is indicative of an inflammatory state in the subject.
2. The method of claim 1 wherein the level of said A<sub>3</sub>AR expression in the WBC is compared to a control level, the control level being the level of A<sub>3</sub>AR expression in normal WBC of a healthy subject, or being a standard reference level for the A<sub>3</sub>AR expression which is indicative of a normal state.
3. The method according to claim 1, wherein the inflammatory state is the result of an autoimmune disease.
4. The method according to claim 3, wherein the autoimmune disease is rheumatoid arthritis (RA).
5. A method for determining the severity of an inflammatory state in a subject comprising:
  - (a) obtaining from the subject a sample comprising WBC;
  - (b) determining the level of expression of A<sub>3</sub>AR in the WBC of said sample;
  - (c) providing a calibration curve of the level of A<sub>3</sub>AR in said cells correlated to the severity of the inflammatory state; and
  - (d) comparing the level of expression of A<sub>3</sub>AR in said cells with the levels appearing in the calibration curve, thereby determining the severity of the inflammatory state of the subject.
6. The method according to claim 5, wherein the inflammatory state is the result of an autoimmune disease.
7. The method according to claim 6, wherein the autoimmune disease is rheumatoid arthritis (RA).

8. A method for determining the effectiveness of an anti-inflammatory therapeutic treatment of a subject comprising:
  - (a) obtaining from the subject samples comprising white blood cells (WBC) from at least two discrete time points, at least one of which is during
  - 5 the anti-inflammatory treatment; and
  - (b) determining the level of expression of A<sub>3</sub>AR in the WBC of the samples, wherein a difference is indicative of the effectiveness of the anti-inflammatory therapeutic treatment.
9. The method of claim 8 wherein a first sample is taken at a time point
- 10 prior to initiation of the treatment and a second sample is taken at a time point during the treatment, and wherein a decrease in the level of the A<sub>3</sub>AR expression in the second sample as compared to the first sample is indicative that the treatment is effective.
10. The method of claim 8 wherein a first sample is taken at a time point
- 15 during the treatment and a second sample is taken at a time point during the treatment subsequent to the time point of the first sample, and wherein a decrease in the level of the A<sub>3</sub>AR expression in the second sample as compared to the first sample is indicative that the treatment is effective.
11. The method of claim 8 wherein a first sample is taken at a time point
- 20 during the treatment and a second sample is taken at a time point after the treatment has been discontinued, and wherein an increase in the level of the A<sub>3</sub>AR expression in the second sample as compared to the first sample is indicative that the treatment is effective.
12. The method according to claim 8 wherein said therapeutic treatment
- 25 involves an anti-inflammatory drug.
13. The method according to claim 8, wherein the inflammatory state is the result of an autoimmune disease.
14. The method according to claim 13, wherein the autoimmune disease is rheumatoid arthritis (RA).
- 30 15. A method for selecting a subject to receive anti-inflammatory therapeutic treatment comprising:

- (a) obtaining from the subject a sample comprising WBC;
- (b) determining the level of expression of A<sub>3</sub>AR in the WBC of the sample;
- (c) comparing the level of expression of A<sub>3</sub>AR in the cells with the 5 level of prior determined or obtained standards;

wherein a level of expression of A<sub>3</sub>AR in the cells is above said standards, the subject is selected for anti-inflammatory therapeutic treatment.

16. The method of Claim 15, wherein said sample of WBC is taken from a subject before receiving an anti-inflammatory treatment.

10 17. The method of claim 15, wherein the level of said A<sub>3</sub>AR expression in the WBC is compared to a standard, the standard being the level of A<sub>3</sub>AR expression in normal WBC of a healthy subject, or being a standard reference level for the A<sub>3</sub>AR expression which is indicative of a normal state.

18. The method according to claim 15, wherein the inflammatory state is 15 the result of an autoimmune disease.

19. The method according to claim 18, wherein the autoimmune disease is rheumatoid arthritis (RA).

20. The method of Claim 15, wherein said anti-inflammatory therapeutic treatment comprises providing said subject with an anti-inflammatory amount 20 of IB-MECA.

21. The method of Claim 15, for selecting a candidate for receiving anti-inflammatory therapeutic treatment under clinical studies.

22. The method of claim 21, wherein the level of A<sub>3</sub>AR expression in the WBC is compared to a standard, the standard being the level of A<sub>3</sub>AR 25 expression in normal WBC of a healthy subject, or being a standard reference level for the A<sub>3</sub>AR expression which is indicative of a normal state.

23. The method according to claim 22, wherein the inflammatory state is the result of an autoimmune disease.

24. The method according to claim 23, wherein the autoimmune disease is 30 rheumatoid arthritis (RA).

25. The method of Claim 24, wherein the level of said A<sub>3</sub>AR expression in the WBC is compared to a standard, the standard being the level of A<sub>3</sub>AR expression in WBC of a subject having inflammation, or being a standard reference level for the A<sub>3</sub>AR expression which is indicative of an inflamed state, the inflammation being to an extent above a predetermined threshold.


26. The method according to claim 25, wherein the inflammatory state is the result of an autoimmune disease.

27. The method according to claim 26, wherein the autoimmune disease is rheumatoid arthritis (RA).


10 28. The method of Claim 21, wherein said anti-inflammatory therapeutic treatment comprises providing said subject with an anti-inflammatory amount of IB-MECA.

15


01579515\3-01




**Fig. 1A**




**Fig. 1B**



**Fig. 1C**



**Fig. 1D**



**Fig. 2**




Fig. 3




Fig. 4A





Fig. 4B


01-4\01579515

**Inflamed Tissues**



**Paw**


**Fig. 5A**



**Synovia**

**Fig. 5B**


**Peripheral Hematopoietic Tissue**



**PB MNC**

**Fig. 5C**


**Lymph Node**




**Naïve      AIA      +MTX**

**Fig. 6**

01-4\01579515




**Fig. 7**




**Fig. 8**

01-4\01579515



**Fig. 9**



**Fig. 10**

01-4\01579515